Patient Rating:

No Rating Available?

Michael Allen Pulsipher, M.D.

Patient Rating:

No Rating Available?

Specialties

Languages

  • English
  • Japanese

Clinical Details

Schedule An Appointment Clinical Office Address
(801) 585-0100 Huntsman Cancer Hospital
Clinic 2C/BMT, Blood and Marrow Transplant
1950 Circle of Hope
Salt Lake City, UT 84112
Map
(801) 662-4830 Primary Children's Hospital
Pediatric Hematology/Oncology
100 N Mario Capecchi Drive
Salt Lake City, UT 84113
(801) 662-4700 Primary Children's Hospital
Pediatric Hematology/Oncology
100 N Mario Capecchi Drive
Salt Lake City, UT 84113

Bio

Dr. Pulsipher completed medical school at Stanford University followed by pediatric residency training at the Children’s Hospital of Philadelphia and subspecialty fellowship training in hematology/oncology at the Dana Farber Cancer Institute/Children’s Hospital in Boston. He is board certified in Pediatrics and Pediatric Hematology and Oncology.

Dr. Pulsipher is currently a Professor of Pediatrics at the University of Utah, as well as an adjunct Professor of Medicine in the Division of Hematology and Hematologic Malignancies. He is Director of the Pediatric Blood and Marrow Transplant Program at Primary Children’s Medical Center, which is part of the combined Adult and Pediatric Blood and Marrow Transplant Program, and with his joint appointment with the Department of Medicine, attends in both pediatric and adult bone marrow transplantation

Dr. Pulsipher has been very active in BMT clinical research and has served in national leadership roles in the Children’s Oncology Group, the Blood and Marrow Transplant Clinical Trials Network, the Center for International Blood and Marrow Transplant Research, and the Pediatric Blood and Marrow Transplant Consortium, of which he is currently the Group Chair. His major areas of research focus include innovative approaches to transplantation of children with acute lymphoblastic leukemia, reduced toxicity approaches to transplant, donor safety, and transplantation of bone marrow failure diseases such as aplastic anemia.

For questions regarding Dr. Pulsipher's adult practice at the Huntsman Cancer Institute, or for questions about any of our clinical programs and for assistance identifying the right Hematology specialist for you or your family member, please feel free to contact our Clinical Care Specialist/New Patient Coordinator at (801) 587-4652, or http://www.huntsmancancer.org

For questions regarding Dr. Pulsipher's pediatric practice and the Blood and Marrow Transplant Program at Primary Children's Medical Center, please call (801) 662-4830, or please feel free to contact Stephanie Mortensen, RN-C, Coordinator at Stephanie.Mortensen@imail.org or Shawnda Ussery, RN-C, Coordinator at Shawnda.Ussery@imail.org

Board Certification and Academic Information

Academic Departments Pediatrics - Professor
Internal Medicine - Adjunct Professor
Academic Divisions Hematology/BMT
Pediatric Hematology/Oncology
Board Certification American Board of Pediatrics (Pediatrics)
Cancer Center Programs Experimental Therapeutics

Academic Profile

Board Certification and Academic Information

Academic Departments Pediatrics - Professor
Internal Medicine - Adjunct Professor
Academic Divisions Hematology/BMT
Pediatric Hematology/Oncology
Board Certification American Board of Pediatrics (Pediatrics)
Cancer Center Programs Experimental Therapeutics

Academic Office Locations

Academic Office Phone Number Academic Office Address
(801) 585-3229 School of Medicine
Hematology/BMT
30 N Medical Dr
Salt Lake City, UT 84132

Academic Bio

Dr. Pulsipher completed medical school at Stanford University followed by pediatric residency training at the Children’s Hospital of Philadelphia and subspecialty fellowship training in hematology/oncology at the Dana Farber Cancer Institute/Children’s Hospital in Boston. His first academic appointment was as an Instructor in Pediatrics at Harvard Medical School where he studied marrow failure disorders. He accepted an appointment as an Assistant Professor at the University of Utah in 2000 and currently is a tenured Professor of Pediatrics. He is an investigator at the Huntsman Cancer Institute and a member of the Experimental Therapeutics Program.

Dr. Pulsipher is currently the Director of the Pediatric Blood and Marrow Transplant Program at Primary Children’s Medical Center, having served as the Director of the combined adult and pediatric Utah Blood and Marrow Transplant Program from 2005-2007 and as the Clinical Director of the adult BMT program, currently housed at the Huntsman Cancer Institute, from 2007-2009.

Dr. Pulsipher’s areas of research focus include innovative approaches to transplantation of children with acute lymphoblastic leukemia, reduced toxicity approaches to transplant, donor safety, and transplantation of bone marrow failure diseases such as aplastic anemia. He has more than 150 publications and abstracts and significant funding through the NIH, the St. Baldrick’s Foundation, and other private funding sources. His research interests have led to national and international leadership roles in the Children’s Oncology Group, the Blood and Marrow Transplant Clinical Trials Network, the Center for International Blood and Marrow Transplant Research, and the Pediatric Blood and Marrow Transplant Consortium, of which he is currently the Group Chair. Dr. Pulsipher also serves as one of 20 selected experts in pediatric oncology on the National Cancer Institute’s Pediatric Physician’s Data Query Board.

Education

Education History

Type School Degree
Fellowship Children's Hospital/Dana Farber Cancer Institute
Pediatric Hematology/Oncology
Fellow
Residency Children's Hospital of Philadelphia
Pediatrics
Resident
Internship Children's Hospital of Philadelphia
Pediatrics
Intern
Professional Medical Stanford University School of Medicine
M.D.
Undergraduate Brigham Young University
Chemistry
B.A.

Publications

Selected Provider Publications

Journal Article

  1. Hitzler JK, He W, Doyle J, Cairo M, Camitta BM, Chan KW, Perez MA, Fraser C, Gross TG, Horan JT, Kennedy-Nasser AA, Kitko C, Kurtzberg J, Lehmann L, OBrien T, Pulsipher MA, Smith FO, Zhang MJ, Eapen M, Carpenter PA (2014). Outcome of transplantation for acute lymphoblastic leukemia in children with down syndrome.LID - 10.1002/pbc.24918 [doi]. Pediatr Blood Cancer.
  2. Bitan M, He W, Zhang MJ, Abdel-Azim H, Ayas MF, Bielorai B, Carpenter PA, Cairo MS, Diaz MA, Horan JT, Jodele S, Kitko CL, Schultz KR, Kletzel M, Kasow KA, Lehmann LE, Mehta PA, Shah N, Pulsipher MA, Prestidge T, Seber A, Shenoy S, Woolfrey AE, Yu LC, Davies SM (2014). Transplantation for children with acute myeloid leukemia: a comparison of outcomes with reduced intensity and myeloablative regimens. Blood, 123(10), 1615-20.
  3. Pulsipher MA, Langholz B, Wall DA, Schultz KR, Bunin N, Carroll WL, Raetz E, Gardner S, Gastier-Foster JM, Howrie D, Goyal RK, Douglas JG, Borowitz M, Barnes Y, Teachey DT, Taylor C, Grupp SA (2014). The addition of sirolimus to tacrolimus/methotrexate GVHD prophylaxis in children with ALL: a phase 3 Children's Oncology Group/Pediatric Blood and Marrow Transplant Consortium trial. Blood, 123(13), 2017-25.
  4. McClune BL, Ahn KW, Wang HL, Antin JH, Artz AS, Cahn JY, Deol A, Freytes CO, Hamadani M, Holmberg LA, Jagasia MH, Jakubowski AA, Kharfan-Dabaja MA, Lazarus HM, Miller AM, Olsson R, Pedersen TL, Pidala J, Pulsipher MA, Rowe JM, Saber W, van Besien KW, Waller EK, Aljurf MD, Akpek G, Bacher U, Chao NJ, Chen YB, Cooper BW, Dehn J, de Lima MJ, Hsu JW, Lewis ID, Marks DI, McGuirk J, Cairo MS, Schouten HC, Szer J, Ramanathan M, Savani BN, Seftel M, Socie G, Vij R, Warlick ED, Weisdorf DJ (2014). Allotransplantation for Patients Age >/=40 Years with Non-Hodgkin Lymphoma: Encouraging Progression-Free Survival.LID - S1083-8791(14)00162-1 [pii]LID - 10.1016/j.bbmt.2014.03.013 [doi]. Biol Blood Marrow Transplant.
  5. Aplenc R, Zhang MJ, Sung L, Zhu X, Ho V, Cooke K, Dvorak C, Hale G, Isola L, Lazarus H, McCarthy P, Olsson R, Pulsipher M, Pasquini M, Bunin N (2014). Effect of body mass in children with hematologic malignancies undergoing allogeneic bone marrow transplantation. Blood.
  6. Pulsipher MA, Chitphakdithai P, Logan BR, Shaw BE, Wingard JR, Lazarus HM, Waller EK, Seftel M, Stroncek DF, Lopez AM, Maharaj D, Hematti P, ODonnell PV, Loren AW, Leitman SF, Anderlini P, Goldstein SC, Levine JE, Navarro WH, Miller JP, Confer DL (2013). Acute toxicities of unrelated bone marrow versus peripheral blood stem cell donation: results of a prospective trial from the National Marrow Donor Program. Blood, 121(1), 197-206.
  7. Taylor DS, Dharmar M, Urquhart-Scott E, Ryan R, Pulsipher MA, Gamis A, Schultz K, Marcin JP (2013). Relationship between pediatric blood and marrow transplant center volume and day +100 mortality: Pediatric Blood and Marrow Transplant Consortium experience. Bone Marrow Transplant, 48(4), 514-22.
  8. Goyal RK, Han K, Wall DA, Pulsipher MA, Bunin N, Grupp SA, Mada SR, Venkataramanan R (2013). Sirolimus pharmacokinetics in early postmyeloablative pediatric blood and marrow transplantation. Biol Blood Marrow Transplant, 19(4), 569-75.
  9. Hale GA, Arora M, Ahn KW, He W, Camitta B, Bishop MR, Bitan M, Cairo MS, Chan K, Childs RW, Copelan E, Davies SM, Perez MA, Doyle JJ, Gale RP, Vicent MG, Horn BN, Hussein AA, Jodele S, Kamani NR, Kasow KA, Kletzel M, Lazarus HM, Lewis VA, Myers KC, Olsson R, Pulsipher M, Qayed M, Sanders JE, Shaw PJ, Soni S, Stiff PJ, Stadtmauer EA, Ueno NT, Wall DA, Grupp SA (2013). Allogeneic hematopoietic cell transplantation for neuroblastoma: the CIBMTR experience. Bone Marrow Transplant, 48(8), 1056-64.
  10. Hitzler JK, He W, Doyle J, Cairo M, Camitta BM, Chan KW, Diaz Perez MA, Fraser C, Gross TG, Horan JT, Kennedy-Nasser AA, Kitko C, Kurtzberg J, Lehmann L, OBrien T, Pulsipher MA, Smith FO, Zhang MJ, Eapen M, Carpenter PA (2013). Outcome of transplantation for acute myelogenous leukemia in children with Down syndrome. Biol Blood Marrow Transplant, 19(6), 893-7.
  11. Storb R, Gyurkocza B, Storer BE, Sorror ML, Blume K, Niederwieser D, Chauncey TR, Pulsipher MA, Petersen FB, Sahebi F, Agura ED, Hari P, Bruno B, McSweeney PA, Maris MB, Maziarz RT, Langston AA, Bethge W, Vindelov L, Franke GN, Laport GG, Yeager AM, Hubel K, Deeg HJ, Georges GE, Flowers ME, Martin PJ, Mielcarek M, Woolfrey AE, Maloney DG, Sandmaier BM (2013). Graft-versus-host disease and graft-versus-tumor effects after allogeneic hematopoietic cell transplantation. J Clin Oncol, 31(12), 1530-8.
  12. Savage SA, Pulsipher MA, Romano A, Berlyne D (2013). Aplastic Anemia & MDS International Foundation (AA&MDSIF): bone marrow failure disease scientific symposium 2012. Leuk Res, 37(7), 848-51.
  13. Pulsipher MA (2013). Better BMT for Hurler syndrome--on the level? Blood, 121(19), 3785-7.
  14. Kornblit B, Maloney DG, Storb R, Storek J, Hari P, Vucinic V, Maziarz RT, Chauncey TR, Pulsipher MA, Bruno B, Petersen FB, Bethge WA, Hubel K, Bouvier ME, Fukuda T, Storer BE, Sandmaier BM (2013). Fludarabine and 2-Gy TBI is superior to 2 Gy TBI as conditioning for HLA-matched related hematopoietic cell transplantation: a phase III randomized trial. Biol Blood Marrow Transplant, 19(9), 1340-7.
  15. Dvorak CC, Cowan MJ, Logan BR, Notarangelo LD, Griffith LM, Puck JM, Kohn DB, Shearer WT, OReilly RJ, Fleisher TA, Pai SY, Hanson IC, Pulsipher MA, Fuleihan R, Filipovich A, Goldman F, Kapoor N, Small T, Smith A, Chan KW, Cuvelier G, Heimall J, Knutsen A, Loechelt B, Moore T, Buckley RH (2013). The natural history of children with severe combined immunodeficiency: baseline features of the first fifty patients of the primary immune deficiency treatment consortium prospective study 6901. J Clin Immunol, 33(7), 1156-64.
  16. Shereck E, Shenoy S, Pulsipher M, Burns L, Bracey A, Chell J, Snyder E, Nemecek E (2013). Exposure of early pediatric trainees to blood and marrow transplantation leads to higher recruitment to the field. Biol Blood Marrow Transplant, 19(9), 1399-402.

Review

  1. Grupp SA, Dvorak CC, Nieder ML, Levine JE, Wall DA, Langholz B, Pulsipher MA (2013). Children's Oncology Group's 2013 blueprint for research: stem cell transplantation. [Review]. Pediatr Blood Cancer, 60(6), 1044-7.

Letter

  1. Chen K, Wu W, Mathew D, Zhang Y, Browne SK, Rosen LB, McManus MP, Pulsipher MA, Yandell M, Bohnsack JF, Jorde LB, Notarangelo LD, Walter JE (2014). Autoimmunity due to RAG deficiency and estimated disease incidence in RAG1/2 mutations [Letter to the editor]. J Allergy Clin Immunol, 133(3), 880-2.e10.

Other

  1. Schultz RK, Baker KS, Boelens JJ, Bollard CM, Egeler RM, Cowan M, Ladenstein R, Lankester A, Locatelli F, Lawitschka A, Levine JE, Loh M, Nemecek E, Niemeyer C, Prasad VK, Rocha V, Shenoy S, Strahm B, Veys P, Wall D, Bader P, Grupp SA, Pulsipher MA, Peters C (2013). Challenges and opportunities for international cooperative studies in pediatric hematopoeitic cell transplantation: priorities of the Westhafen Intercontinental Group. Biol Blood Marrow Transplant (19(9), pp. 1279-87). United States.

Clinical Trials

Clinical Trials

Video & News